Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12,077 Mln
P/E Ratio
28.5
P/B Ratio
2.15
Industry P/E
--
Debt to Equity
0.11
ROE
0.08 %
ROCE
6.94 %
Div. Yield
0 %
Book Value
28.78
EPS
2.17
CFO
$261.71 Mln
EBITDA
$-347.99 Mln
Net Profit
$-54.92 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Biomarin Pharmaceutical Inc (BMRN)
| -3.83 | -11.52 | -0.39 | -23.04 | -8.07 | -7.77 | -5.82 |
|
BSE Sensex
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Midcap 400
| -9.36 | -3.08 | -13.56 | -2.99 | 4.16 | 10.72 | 6.40 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Biomarin Pharmaceutical Inc (BMRN)
| -31.62 | -6.83 | 17.14 | 0.75 | 3.71 | -0.70 | -4.48 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 120.47 | 17,534.46 | 10.65 | 10.36 | |
| 140.21 | 33,394.36 | 25.79 | -- | |
| 899.45 | 787,796.72 | 75.11 | 84.41 | |
| 155.66 | 374,629.66 | 17.26 | 29.42 |
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia... Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California. Address: 770 Lindaro Street, San Rafael, CA, United States, 94901 Read more
CFO & Executive VP
Mr. Brian R. Mueller
CFO & Executive VP
Mr. Brian R. Mueller
Headquarters
San Rafael, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Biomarin Pharmaceutical Inc (BMRN) stood at $ 6,989 Mln as on 31-Dec-24
The share price of Biomarin Pharmaceutical Inc (BMRN) is $63.21 (NASDAQ) as of 30-Apr-2025 14:45 EDT. Biomarin Pharmaceutical Inc (BMRN) has given a return of -8.07% in the last 3 years.
Biomarin Pharmaceutical Inc (BMRN) has a market capitalisation of $ 12,077 Mln as on 29-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/E ratio of Biomarin Pharmaceutical Inc (BMRN) is 28.50 times as on 29-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biomarin Pharmaceutical Inc (BMRN) and enter the required number of quantities and click on buy to purchase the shares of Biomarin Pharmaceutical Inc (BMRN).
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California. Address: 770 Lindaro Street, San Rafael, CA, United States, 94901
The CEO & director of Mr. Brian R. Mueller. is Biomarin Pharmaceutical Inc (BMRN), and CFO & Sr. VP is Mr. Brian R. Mueller.
There is no promoter pledging in Biomarin Pharmaceutical Inc (BMRN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3,247
|
|
|
1,740
|
|
|
74,481
|
|
|
38,015
|
| Biomarin Pharmaceutical Inc (BMRN) | Ratios |
|---|---|
|
Return on equity(%)
|
8.05
|
|
Operating margin(%)
|
19.42
|
|
Net Margin(%)
|
14.96
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Biomarin Pharmaceutical Inc (BMRN) was $427 Mln.
$-0.07
(
